Cited by 354Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesSphingolipid Metabolism and Signaling

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Open access

Cox, Adrienne D., Der, Channing J., Philips, Mark R.·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-3214PMC PMC4400837

Open this paper in CoChat — free account

Abstract

RAS proteins require membrane association for their biologic activity, making this association a logical target for anti-RAS therapeutics. Lipid modification of RAS proteins by a farnesyl isoprenoid is an obligate step in that association, and is an enzymatic process. Accordingly, farnesyltransferase inhibitors (FTI) were developed as potential anti-RAS drugs. The lack of efficacy of FTIs as anticancer drugs was widely seen as indicating that blocking RAS membrane association was a flawed approach to cancer treatment. However, a deeper understanding of RAS modification and trafficking has revealed that this was an erroneous conclusion. In the presence of FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become substrates for alternative modification, can still associate with membranes, and can still function. Thus, FTIs failed not because blocking RAS membrane association is an ineffective approach, but because FTIs failed to accomplish that task. Recent findings regarding RAS isoform trafficking and the regulation of RAS subcellular localization have rekindled interest in efforts to target these processes. In particular, improved understanding of the palmitoylation/depalmitoylation cycle that regulates RAS interaction with the plasma membrane, endomembranes, and cytosol, and of the potential importance of RAS chaperones, have led to new approaches. Efforts to validate and target other enzymatically regulated posttranslational modifications are also ongoing. In this review, we revisit lessons learned, describe the current state of the art, and highlight challenging but promising directions to achieve the goal of disrupting RAS membrane association and subcellular localization for anti-RAS drug development. Clin Cancer Res; 21(8); 1819–27. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-3214

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“The three RAS genes (HRAS, NRAS, KRAS) are the most commonly mutated oncogenes in human cancers (1,2).”
Background
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citation
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,042
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms
Rocks, O., Peyker, A., Kahms, M., Verveer, P., Koerner, C., Lumbierres, M., Kuhlmann, J., Waldmann, H., Wittinghofer, A., & Bastiaens, P. (2005) · Science · doi:10.1126/science.1105654 · Cited by 866
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Self-citation
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 3×
“Such inhibitors have been developed and some have reached the clinic (16,17), but have been limited by toxicity (21-23).”
Background
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1×
“RAS association with the plasma membrane (PM) and with other membrane compartments upon which signaling occurs (10,11) is promoted by a welldescribed series of post-translational modifications at RAS C-terminal CAAX motifs (Fig.”
BackgroundSelf-citation
The p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K. M., Bar‐Sagi, D., & Philips, M. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 578
Self-citation
K-ras is an essential gene in the mouse with partial functional overlap with N-rasPreprint
Johnson, L., Greenbaum, D. C., Cichowski, K. M., Mercer, K. L., Murphy, E. A., Schmitt, E. S., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 540
A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.
Hancock, J. F., Cadwallader, K. A., Paterson, H., & Marshall, C. J. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04979.x · Cited by 482
PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Self-citation
The Palmitoylation Machinery Is a Spatially Organizing System for Peripheral Membrane Proteins
Rocks, O., Gerauer, M., Vartak, N., Koch, S., Huang, Z., Pechlivanis, M., Kuhlmann, J., Brunsveld, L., Chandra, A., Ellinger, B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.007 · Cited by 454
Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1
Bivona, T. G., de Castro, I. P., Ahearn, I. M., Grana, T. M., Chiu, V. K., Lockyer, P. J., Cullen, P. J., Pellicer, À., Cox, A. D., & Philips, M. R. (2003) · Nature · doi:10.1038/nature01806 · Cited by 401
Self-citation
Small-molecule inhibition of APT1 affects Ras localization and signaling.
Dekker, F., Rocks, O., Vartak, N., Menninger, S., Hedberg, C., Balamurugan, R., Wetzel, S., Renner, S., Gerauer, M., Schölermann, B., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.362 · Cited by 401
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes
Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26802 · Cited by 361
Self-citation
DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras
Swarthout, J. T., Lobo, S., Farh, L., Croke, M., Greentree, W. K., Deschenes, R. J., & Linder, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504113200 · Cited by 356
Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras
Wright, L. P., & Philips, M. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600004-jlr200 · Cited by 340
Self-citation
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338
Self-citation
Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor
Antal, C. E., Hudson, A., Kang, E., Zanca, C., Wirth, C., Stephenson, N. L., Trotter, E. W., Gallegos, L. L., Miller, C. J., Furnari, F. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.001 · Cited by 331
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway
Goodwin, J., Drake, K. R., Rogers, C., Wright, L. P., Lippincott-Schwartz, J., Philips, M., & Kenworthy, A. (2005) · Journal of Cell Biology · doi:10.1083/jcb.200502063 · Cited by 308
Self-citation
Mammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum
Dai, Q., Choy, E., Chiu, V. K., Romano, J. D., Slivka, S. R., Steitz, S. A., Michaelis, S., & Philips, M. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15030 · Cited by 296
Self-citation
Proteome Scale Characterization of Human S-Acylated Proteins in Lipid Raft-enriched and Non-raft Membranes
Yang, W., Vizio, D. D., Kirchner, M., Steen, H., & Freeman, M. R. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800448-mcp200 · Cited by 268
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252
KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport
Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243 · cited 1×
“Phosphodiesterase-6δ (PDE6δ) has been variously proposed to chaperone NRAS (46,59) or nonpalmitoylated HRAS (59), and KRAS4B (46,60-62) but not KRAS4A (46).”
Background
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 238
Self-citation
Metabolic Dependencies in RAS -Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 230
Ras membrane orientation and nanodomain localization generate isoform diversity
Abankwa, D., Gorfe, A. A., Inder, K. L., & Hancock, J. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903907107 · Cited by 223
Dislodgment and Accelerated Degradation of Ras
Haklai, R., Gana‐Weisz, M., Elad, G., Paz, A., Marciano, D., Egozi, Y., Ben‐Baruch, G., & Kloog, Y. (1998) · Biochemistry · doi:10.1021/bi972032d · Cited by 195
Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage
Schmidt, W. K., Tam, A. S. P., Fujimura‐Kamada, K., & Michaelis, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11175 · Cited by 186
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells
Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Sinensky, M. S., Beck, L. A., Leonard, S. S., & Evans, R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45464-0 · Cited by 172
Notch1 Functions as a Tumor Suppressor in a Model of K-ras–Induced Pancreatic Ductal Adenocarcinoma
Hanlon, L., Avila, J. L., Demarest, R. M., Troutman, S. A., Allen, M., Ratti, F., Rustgi, A. K., Stanger, B. Z., Radtke, F., Adsay, V. N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4645 · Cited by 172
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 168
Isoprenylcysteine Carboxyl Methyltransferase Deficiency in Mice
Bergö, M. O., Leung, G. K. C., Ambroziak, P., Otto, J. C., Casey, P. J., Gomes, A. Q., Seabra, M. C., & Young, S. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000831200 · Cited by 162
Deletion of PrBP/δ impedes transport of GRK1 and PDE6 catalytic subunits to photoreceptor outer segments
Zhang, H., Li, S., Doan, T. A., Rieke, F. M., Detwiler, P. B., Frederick, J. M., & Baehr, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701681104 · Cited by 160
Galectin-1(L11A) Predicted from a Computed Galectin-1 Farnesyl-Binding Pocket Selectively Inhibits Ras-GTP
Rotblat, B., Niv, H., André, S., Kaltner, H., Gabius, H., & Kloog, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0026 · Cited by 160
Dynamic Palmitoylation Links Cytosol-Membrane Shuttling of Acyl-protein Thioesterase-1 and Acyl-protein Thioesterase-2 with That of Proto-oncogene H-Ras Product and Growth-associated Protein-43
Kong, E., Peng, S., Chandra, G., Sarkar, C., Zhang, Z., Bagh, M. B., & Mukherjee, A. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421073 · Cited by 153
Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters.
Belanis, L., Plowman, S. J., Rotblat, B., Hancock, J., & Kloog, Y. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-10-1053 · Cited by 147
Targeting protein lipidation in disease
Resh, M. D. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.01.007 · Cited by 145
Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation
Bergö, M. O., Ambroziak, P., Gregory, C., George, A. M., Otto, J. C., Kim, E. J.-H., Nagase, H., Casey, P. J., Balmain, A., & Young, S. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.171-181.2002 · Cited by 142
K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3
Shalom‐Feuerstein, R., Plowman, S. J., Rotblat, B., Ariotti, N., Tian, T., Hancock, J. F., & Kloog, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1117 · Cited by 141
Signal Integration by Lipid-Mediated Spatial Cross Talk between Ras Nanoclusters
Zhou, Y., Hong, L., Rodkey, T. L., Ariotti, N., Parton, R. G., & Hancock, J. F. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01227-13 · Cited by 133
Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain
Laude, A., & Prior, I. A. (2008) · Journal of Cell Science · doi:10.1242/jcs.020107 · Cited by 131
Inhibition of cell growth by lovastatin is independent of ras function.
DeClue, J. E., Vass, W. C., Papageorge, A. G., Lowy, D. R., & Willumsen, B. M. (1991) · PubMed · Cited by 131
The δ Subunit of Retinal Rod cGMP Phosphodiesterase Regulates the Membrane Association of Ras and Rap GTPases
Nancy, V., Callebaut, I., Marjou, A. E., & de Gunzburg, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109983200 · Cited by 124
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121
FKBP12 Binds to Acylated H-Ras and Promotes Depalmitoylation
Ahearn, I. M., Tsai, F. D., Court, H., Zhou, M., Jennings, B. C., Ahmed, M., Fehrenbacher, N., Linder, M. E., & Philips, M. R. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.001 · Cited by 115
Self-citation
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
Liu, M., Sjogren, A.-K. M., Karlsson, C., Ibrahim, M. X., Andersson, K., Olofsson, F. J., Wahlstrom, A. M., Dalin, M. G., Yu, H., Chen, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908396107 · Cited by 113
Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission
van der Hoeven, D., Cho, K.-J., Ma, X., Chigurupati, S., Parton, R. G., & Hancock, J. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00884-12 · Cited by 113
Marine natural products: Bryostatins in preclinical and clinical studies
Kollár, P., Rajchard, J., Balounová, Z., & Pazourek, J. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.804100 · Cited by 110
Palmitoylation of oncogenic NRAS is essential for leukemogenesis
Cuiffo, B., & Ren, R. (2010) · Blood · doi:10.1182/blood-2009-03-213876 · Cited by 110
Electrostatic Interactions Positively Regulate K-Ras Nanocluster Formation and Function
Plowman, S. J., Ariotti, N., Goodall, A., Parton, R. G., & Hancock, J. F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-08 · Cited by 108
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
Laheru, D. A., Shah, P., Rajeshkumar, N. V., McAllister, F. M., Taylor, G., Goldsweig, H. G., Le, D. T., Donehower, R. C., Jimeno, A., Linden, S., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9818-6 · Cited by 104
Staurosporines Disrupt Phosphatidylserine Trafficking and Mislocalize Ras Proteins
Cho, K.-J., Park, J.-H., Piggott, A. M., Salim, A. A., Alemayehu, A. G., Parton, R. G., Capon, R. J., Lacey, E., & Hancock, J. F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424457 · Cited by 94
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K., Young, S. G., & Bergö, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 93
The Autodepalmitoylating Activity of APT Maintains the Spatial Organization of Palmitoylated Membrane Proteins
Vartak, N., Papke, B., Grecco, H. E., Roßmannek, L., Waldmann, H., Hedberg, C., & Bastiaens, P. I. H. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2013.11.024 · Cited by 89
Distinct Rates of Palmitate Turnover on Membrane-bound Cellular and Oncogenic H-Ras
Baker, T. L., Zheng, H., Walker, J., Coloff, J. L., & Buss, J. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206956200 · Cited by 88
Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors
Sung, P. J., Tsai, F. D., Vais, H., Court, H., Yang, J., Fehrenbacher, N., Foskett, J. K., & Philips, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306431110 · Cited by 86
Self-citation
Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras
Farin, K., Trangle, S. S., Haklai, R., Cohen-Or, I., Elad‐Sfadia, G., Reyes-Reyes, M. E., Bates, P. J., Cox, A. D., Kloog, Y., & Pinkas‐Kramarski, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2887 · Cited by 86
Self-citation
Novel determinants of H-Ras plasma membrane localization and transformation.
Willumsen, B. M., Cox, A. D., Solski, P. A., Der, C. J., & Buss, J. E. (1996) · PubMed · Cited by 86
Self-citation
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
Xu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K. (2011) · Blood · doi:10.1182/blood-2011-06-358960 · Cited by 80
Development of Highly Potent Inhibitors of the Ras‐Targeting Human Acyl Protein Thioesterases Based on Substrate Similarity Design
Hedberg, C., Dekker, F. J., Rusch, M., Renner, S., Wetzel, S., Vartak, N., Gerding‐Reimers, C., Bon, R. S., Bastiaens, P. I. H., & Waldmann, H. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201102965 · Cited by 80
Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid
Elad, G., Paz, A., Haklai, R., Marciano, D., Cox, A. D., & Kloog, Y. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(99)00144-5 · Cited by 77
Self-citation
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch
Ashery, U., Yizhar, O., Rotblat, B., Elad‐Sfadia, G., Barkan, B., Haklai, R., & Kloog, Y. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9059-3 · Cited by 74
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergö, M. O. (2006) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 72
Nucleophosmin and Nucleolin Regulate K-Ras Plasma Membrane Interactions and MAPK Signal Transduction
Inder, K. L., Lau, C., Loo, D., Chaudhary, N., Goodall, A., Martin, S., Jones, A., van der Hoeven, D., Parton, R. G., Hill, M. M. C., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.001537 · Cited by 71
On the Physiological Importance of Endoproteolysis of CAAX Proteins
Bergö, M. O., Lieu, H. D., Gavino, B. J., Ambroziak, P., Otto, J. C., Casey, P. J., Walker, Q. M., & Young, S. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310081200 · Cited by 67
Structure Guided Design and Kinetic Analysis of Highly Potent Benzimidazole Inhibitors Targeting the PDEδ Prenyl Binding Site
Zimmermann, G., Schultz‐Fademrecht, C., Küchler, P., Murarka, S., Ismail, S., Triola, G., Nußbaumer, P., Wittinghofer, A., & Waldmann, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500632s · Cited by 64
Small-Molecule Inhibitors of the Rce1p CaaX Protease
Manandhar, S. P., Hildebrandt, E. R., & Schmidt, W. K. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107307226 · Cited by 64
An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo
Lau, H. Y., Ramanujulu, P. M., Guo, D., Yang, T., Wirawan, M., Casey, P. J., Go, M., & Wang, M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29692 · Cited by 63
Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth
Barceló, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota‐Rabassedas, N., Jaumot, M., Vilardell, F., Capellá, G., & Agell, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1750 · Cited by 62
Dual Protein Farnesyltransferase−Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents
DeSolms, S. J., Ciccarone, T. M., MacTough, S. C., Shaw, A. W., Buser, C. A., Ellis-Hutchings, M., Fernandes, C., Hamilton, K., Huber, H. E., Kohl, N. E., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020587n · Cited by 60
Calmodulin Prevents Activation of Ras by PKC in 3T3 Fibroblasts
Villalonga, P., López-Alcalá, C., Chiloeches, A., Gil, J., Marais, R., Bachs, O., & Agell, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202245200 · Cited by 56
Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)
Judd, W. R., Slattum, P. M., Hoang, K. C., Bhoite, L. T., Valppu, L., Alberts, G. L., Brown, B., Roth, B. L., Ostanin, K., Huang, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200249a · Cited by 56
Targeting protein palmitoylation: selective inhibitors and implications in disease
Chavda, B., Arnott, J. A., & Planey, S. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.933802 · Cited by 55
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression
Court, H., Amoyel, M., Hackman, M., Lee, K. E., Xu, R., Miller, G., Bar‐Sagi, D., Bach, E. A., BergÃ¶, M. O., & Philips, M. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65764 · Cited by 54
Self-citation
Multiple Cellular Proteins Modulate the Dynamics of K-ras Association with the Plasma Membrane
Bhagatji, P., Leventis, R., Rich, R. L., Lin, C., & Silvius, J. R. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.10.001 · Cited by 51
A Distinct Class of Dominant Negative Ras Mutants
Fiordalisi, J. J., Holly, S. P., Johnson, R. L., Parise, L. V., & Cox, A. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107684200 · Cited by 44
Self-citation
Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2
Cho, K.-J., Hill, M. M. C., Chigurupati, S., Du, G., Parton, R. G., & Hancock, J. F. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00989-10 · Cited by 44
RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments
Christiansen, J. R., Kolandaivelu, S., Bergö, M. O., & Ramamurthy, V. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103627108 · Cited by 43
Profiling and inhibiting reversible palmitoylation
Hernandez, J. L., Majmudar, J. D., & Martin, B. R. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.11.023 · Cited by 42
Boron‐Based Inhibitors of Acyl Protein Thioesterases 1 and 2
Zimmermann, T. J., Bürger, M., Tashiro, E., Kondoh, Y., Martinez, N. E., Görmer, K., Rosin‐Steiner, S., Shimizu, T., Ozaki, S., Mikoshiba, K., et al. (2012) · ChemBioChem · doi:10.1002/cbic.201200571 · Cited by 36
Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling
Song, S.-P., Hennig, A., Schubert, K., Markwart, R., Schmidt, P., Prior, I. A., Böhmer, F.-D., & Rubio, I. (2013) · Biochemical Journal · doi:10.1042/bj20121799 · Cited by 27
Prenylcysteine carboxylmethyltransferase is essential for the earliest stages of liver development in mice
Lin, X., Jung, J., Kang, D., Xu, B., Zaret, K. S., & Zoghbi, H. Y. (2002) · Gastroenterology · doi:10.1053/gast.2002.34279 · Cited by 22
Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association
Tamanoi, F., & Lu, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00008-1 · Cited by 18
Chemical approaches for profiling dynamic palmitoylation
Martin, B. R. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120271 · Cited by 18
Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteases
Dechert, A.-M. R., MacNamara, J. P., Breevoort, S. R., Hildebrandt, E. R., Hembree, N. W., Rea, A. C., McLain, D. E., Porter, S. B., Schmidt, W. K., & Dore, T. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.041 · Cited by 18
Endoproteolytic Processing of RhoA by Rce1 Is Required for the Cleavage of RhoA by Yersinia enterocolitica Outer Protein T
Fueller, F., Bergö, M. O., Young, S. G., Aktories, K., & Schmidt, G. (2006) · Infection and Immunity · doi:10.1128/iai.74.3.1712-1717.2006 · Cited by 18
Inhibitors of K-Ras Plasma Membrane Localization
Cho, K.-J., van der Hoeven, D., & Hancock, J. F. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00011-7 · Cited by 16
Chaperone-mediated specificity in Ras and Rap signaling
Azoulay‐Alfaguter, I., Strazza, M., & Mor, A. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.989308 · Cited by 12
Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1)
Adibekian, A., Martin, B. R., Chang, J. W., Hsu, K., Tsuboi, K., Bachovchin, D. A., Speers, A. E., Brown, S. J., Spicer, T., Fernández-Vega, V., et al. (2014) · Europe PMC (PubMed Central) · Cited by 11
Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2)
Adibekian, A., Martin, B. R., Chang, J. W., Hsu, K., Tsuboi, K., Bachovchin, D. A., Speers, A. E., Brown, S. J., Spicer, T., Fernández-Vega, V., et al. (2014) · Cited by 10
Ras Chaperones
Kloog, Y., Elad‐Sfadia, G., Haklai, R., & Mor, A. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00012-9 · Cited by 8
Protein localization: Can too much lipid glue stop Ras?
Cox, A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.399 · Cited by 6
Self-citation

Sorted by citations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Self-citation
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721

See all 354

Authors: Cox, A. D., Der, C. J., & Philips, M. R.
Affiliations: University of North Carolina at Chapel Hill (US)
NYU Langone Health (US)
ORCID: Cox, Adrienne D.
Der, Channing J.
Philips, Mark R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-04-14
Volume: 21
Issue: 8
Pages: 1819-1827
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-3214
PMC: PMC4400837
OpenAlex: W2129653056
Cited by: 351
References: 105
Citations by year: 2026: 11 · 2025: 15 · 2024: 19 · 2023: 31 · 2022: 30 · 2021: 46 · 2020: 39 · 2019: 29 · 2018: 43 · 2017: 40 · 2016: 28 · 2015: 18
FWCI: 4.17
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
UNC Libraries
Funders: Pancreatic Cancer Action Network
National Institutes of Health (5r01ca042978-30)
National Cancer Institute (R01CA116034, R01CA175747, R01CA163489, R01-CA042978, R21CA179193)
National Institute of General Medical Sciences (R01GM055279)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords: farnesyltransferase inhibitors, KRAS, NRAS, depalmitoylation, post-translational modification, RAS-driven cancers
MeSH terms: Acetyltransferases, Acylation, Animals, Antineoplastic Agents, Carrier Proteins, Cell Membrane, Humans, Neoplasms, Endopeptidases, Phosphorylation, Protein Kinase C, Thiolester Hydrolases, Signal Transduction, Proto-Oncogene Proteins p21(ras), Protein Prenylation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Alkyl and Aryl Transferases, Amino Acid Motifs, Protein Transport, Protein Interaction Domains and Motifs, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks